Oncotype DX recurrence score is used primarily to guide chemotherapy decisions in which subtype of breast cancer?

• A ER-negative, HER2-positive, node-negative early breast cancer
• B Triple-negative breast cancer, T1N0
• C ER-positive, HER2-positive, T2N1 breast cancer
• D ER-positive, HER2-negative, node-negative or 1-3 node-positive, early breast cancer ✓

Explanation

Oncotype DX is a 21-gene expression assay validated to predict 10-year distant recurrence risk and chemotherapy benefit in ER+/HER2- early breast cancer patients (node-negative or 1-3 positive nodes). The TAILORx and RxPONDER trials defined its use: low RS (<18) can safely omit chemotherapy; high RS (≥31) benefits from adding chemotherapy to endocrine therapy. It is not applicable in HER2+ or triple-negative subtypes.

Reference: Bailey & Love's Short Practice of Surgery, 27th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.